Johnson & Johnson (JNJ) Q3 2026 (USD): Adj. EPS 2.59 (exp. 2.67), Revenue 25.4bln (exp. 25.38bln), sees FY26 Adj. EPS between 11.05-11.15 (prev. 10.96-11.11) and Revenue 101-101.4 (prev. 100.8-101.4bln)

A split print of this kind, a bottom-line miss against a broadly in-line top line alongside a raised full-year EPS floor, is a familiar pattern for large-cap diversified healthcare, where guidance trajectory has historically mattered more to the share reaction than the quarterly headline itself. For JNJ specifically, the questions that tend to dominate the call are the litigation overhang, the cadence of the pharma pipeline as key products face loss of exclusivity, and the mix between the pharma and medtech segments, since margin performance in each has driven past repricings in opposite directions. A raised EPS floor with a narrowed revenue range has on previous occasions been read as confidence in cost control rather than demand acceleration, and the tell is whether management attributes the lift to operational items or to one-off factors. Worth watching are the segment-level commentary on the call, any update on talc and other legal provisions, and how the guidance raise compares with the size of the quarterly miss, since a raise that fails to fully absorb the miss has historically capped the initial relief bid. The peer set reaction in large-cap pharma has tended to be limited unless the print signals something sector-wide on pricing or pipeline risk.